Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Wolff AC, et al. Among authors: ellis io. J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30. J Clin Oncol. 2018. PMID: 29846122 Free article.
Loss of CD55 is associated with aggressive breast tumors.
Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Madjd Z, et al. Among authors: ellis io. Clin Cancer Res. 2004 Apr 15;10(8):2797-803. doi: 10.1158/1078-0432.ccr-1073-03. Clin Cancer Res. 2004. PMID: 15102687
Prognostic markers in triple-negative breast cancer.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Rakha EA, et al. Among authors: ellis io. Cancer. 2007 Jan 1;109(1):25-32. doi: 10.1002/cncr.22381. Cancer. 2007. PMID: 17146782 Free article.
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P. Bartlett JM, et al. Among authors: ellis io, ellis p. J Clin Oncol. 2007 Oct 1;25(28):4423-30. doi: 10.1200/JCO.2007.11.0973. J Clin Oncol. 2007. PMID: 17906205
Basal-like breast cancer: a critical review.
Rakha EA, Reis-Filho JS, Ellis IO. Rakha EA, et al. Among authors: ellis io. J Clin Oncol. 2008 May 20;26(15):2568-81. doi: 10.1200/JCO.2007.13.1748. J Clin Oncol. 2008. PMID: 18487574 Review.
Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ. Webster LR, et al. Among authors: ellis io. Clin Cancer Res. 2008 Oct 15;14(20):6625-33. doi: 10.1158/1078-0432.CCR-08-0701. Clin Cancer Res. 2008. PMID: 18927304 Free article.
Triple-negative/basal-like breast cancer: review.
Rakha EA, Ellis IO. Rakha EA, et al. Among authors: ellis io. Pathology. 2009 Jan;41(1):40-7. doi: 10.1080/00313020802563510. Pathology. 2009. PMID: 19089739 Review.
763 results